Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efgartigimod improves triple-negative myasthenia gravis.
Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Mantegazza R, Antozzi C. Frangiamore R, et al. Neurol Sci. 2024 Mar;45(3):1307-1309. doi: 10.1007/s10072-023-07122-y. Epub 2023 Oct 24. Neurol Sci. 2024. PMID: 37875596 No abstract available.
Development and validation of the Myasthenia Gravis TeleScore (MGTS).
Pasqualin F, Guidoni SV, Albertini E, Ermani M, Frangiamore R, Vanoli F, Antozzi C, Mantegazza R, Bonifati DM. Pasqualin F, et al. Among authors: frangiamore r. Neurol Sci. 2022 Jul;43(7):4503-4509. doi: 10.1007/s10072-022-05918-y. Epub 2022 Feb 28. Neurol Sci. 2022. PMID: 35226211 Free PMC article.
Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study.
Bonanno S, Pasanisi MB, Frangiamore R, Maggi L, Antozzi C, Andreetta F, Campanella A, Brenna G, Cottini L, Mantegazza R. Bonanno S, et al. Among authors: frangiamore r. SAGE Open Med. 2018 Dec 17;6:2050312118819013. doi: 10.1177/2050312118819013. eCollection 2018. SAGE Open Med. 2018. PMID: 30574306 Free PMC article.
Complement Inhibition for the Treatment of Myasthenia Gravis.
Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Mantegazza R, et al. Among authors: frangiamore r. Immunotargets Ther. 2020 Dec 15;9:317-331. doi: 10.2147/ITT.S261414. eCollection 2020. Immunotargets Ther. 2020. PMID: 33365280 Free PMC article. Review.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Multiple Sclerosis Questionnaire for Job Difficulties (MSQ-Job): definition of the cut-off score.
Schiavolin S, Giovannetti AM, Leonardi M, Brenna G, Brambilla L, Confalonieri P, Frangiamore R, Mantegazza R, Moscatelli M, Clerici VT, Cortese F, Covelli V, Ponzio M, Zaratin P, Raggi A. Schiavolin S, et al. Among authors: frangiamore r. Neurol Sci. 2016 May;37(5):777-80. doi: 10.1007/s10072-016-2495-z. Epub 2016 Feb 3. Neurol Sci. 2016. PMID: 26842465
Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
Brambilla L, Rossi Sebastiano D, Aquino D, Torri Clerici V, Brenna G, Moscatelli M, Frangiamore R, Giovannetti AM, Antozzi C, Mantegazza R, Franceschetti S, Bruzzone MG, Erbetta A, Confalonieri P. Brambilla L, et al. Among authors: frangiamore r. J Neurol Sci. 2016 Sep 15;368:402-7. doi: 10.1016/j.jns.2016.06.019. Epub 2016 Jul 2. J Neurol Sci. 2016. PMID: 27538672
27 results